

Sample Medical Document

SM

Encounter Summary

Patient	Tim Johnson
Date of birth	January 25, 1964
Sex	Male
Race	White
Ethnicity	Not Hispanic or Latino
Contact info	Primary Home: 159 OUTER DR DUNDEER,MI48131,USA Tel: +1-313-408-9439
Patient IDs	PRMLMQR2D2GX3QH 1.2.840.114850.1.13.424.2.7.3.688884.100 W108030145 1.2.840.114350.1.13.42455554.2.7.5.698077.502 E3181194 1.2.840.114360.1.13.424.2.7.5.737384.0
Document Id	1.2.840.114350.1.13.424.2.7.8.68844444883.557181648
Document Created:	November 28, 2022, 08:47:28, EST
Performer (primary care physician)	Farook Rahmah, MD of Beaumont Health (Beaumont, Bedford, and Oakwood)
Author	Epic - Version 10.2
Contact info	
Encounter Id	1000059724901 1.2.840.114350.1.13.424.2.7.3.698084.8
Encounter Type	Hospital Encounter
Encounter Date	From May 13, 2020, 08:01:00 -0400 to May 13, 2020, 23:59:00 -0400
Encounter Location	PROMEDICA HERRICK HOSPITAL - LAB DRIVE THRU of
Responsible party	ProMedica Health System
Contact info	Work Place:
Emergency contact	Annie Johnson
Contact info	Tel: +1-927-563-9186
Legal authenticator	Director HIM signed at November 28, 2022, 08:47:29, EST
Contact info	Work Place: ProMedica Health System
Document maintained by	ProMedica Health System
Contact info	Work Place: 5855 Monty St SYLVANIA,NH43860,US

- [Encounter Details](#)
- [Social History](#)
- [Last Filed Vital Signs](#)
- [Functional Status](#)
- [Discharge Instructions](#)
- [Medications at Time of Discharge](#)
- [Plan of Treatment](#)
- [Goals](#)
- [Procedures](#)
- [Results](#)
- [Visit Diagnoses](#)
- [Admitting Diagnoses](#)
- [Administered Medications](#)
- [Additional Health Concerns](#)
- [Care Teams](#)

Encounter Details

Date	Type	Department	Care Team	Description
05/13 /2020	Hospital Encounter	PROMEDICA HERRICK HOSPITAL - LAB DRIVE THRU 500 E POTTAWATAMIE ST TECUMSEH, MI 49286-2018 517-265-0011		Cough (Primary Dx); Sore throat

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Smoking Tobacco: Never Assessed				
Sex Assigned at Birth	Date Recorded			
Not on file				

documented as of this encounter

Last Filed Vital Signs

Not on filedocumented in this encounter

Functional Status

Not on filedocumented as of this encounter

Discharge Instructions

Not on filedocumented in this encounter

Medications at Time of Discharge

Not on filedocumented as of this encounter

Plan of Treatment

Not on file

documented as of this encounter

Goals

Not on filedocumented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
SARS COV 2 BY NAAT /MOLECULAR (CPL)	Routine	05/13/2020 1:00 PM EDT		Results for this procedure are in the results section.
SARS COV 2 (COVID-19)	Routine	05/13/2020 1:00 PM EDT	Cough Sore throat	Results for this procedure are in the results section.

documented in this encounter

Results

- SARS CoV 2 INTERP (CPL) (05/13/2020 1:00 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
COVID-19	NEGATIVE	SEE NOTE		05/14 /2020 4: 42 PM EDT	HERRICK MEDICAL CENTER	
<p>Comment: NOTE SARS-CoV-2 RNA NOT DETECTED Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 have not been determined. Collection of multiple specimens or types of specimens may be necessary to detect virus. Improper specimen collection and handling, sequence variability under primers/probes, or organism present below the limit of detection may lead to false negative results. Positive and negative predictive values of testing are highly dependent on prevalence. False negative test results are more likely when prevalence is high.</p>						
Source	NASOPHARYNGEAL			05/14 /2020 4: 42 PM EDT	HERRICK MEDICAL CENTER	

Comment:**NOTE**

The expected result is Negative (Not Detected).

The SARS-CoV-2 test is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria. For lower respiratory tract specimens, the assay is submitted for authorization by FDA under an Emergency Use Authorization (EUA). Testing methodology is real-time RT-PCR. If received as separate collection devices, nasopharyngeal and oro-pharyngeal specimens are combined for analysis. Additional specimens may be split to a separate accession for analysis and reporting as this test includes a single unit of service.

Test results must be correlated with clinical presentation and evaluated in the context of other laboratory and epidemiologic data. Test performance can be affected because the epidemiology and clinical spectrum of infection caused by SARS-CoV-2 is not fully known. For example, the optimum types of specimens to collect and when during the course of infection these specimens are most likely to contain detectable viral RNA may not be known.

This test has not been Food and Drug Administration (FDA) cleared or approved and has been authorized by FDA under an Emergency Use Authorization (EUA). The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of SARS-CoV-2 under Section 564(b)(1) of the Act, 21 U.S.C. section 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Clinical Pathology Laboratories are certified under the

Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. section 263a, to perform high complexity tests.

Fact Sheet for Healthcare Providers:

<https://tinyurl.com/r7awxyh>

(or: [https://www.cdc.gov/coronavirus/2019-ncov/downloads/](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Factsheet-for-Healthcare-Providers-2019-nCoV.pdf)

Factsheet-for-Healthcare-Providers-2019-nCoV.pdf)

Fact Sheet for Patients:

<https://tinyurl.com/rlqe72t>

(or: [https://www.cdc.gov/coronavirus/2019-ncov/downloads/](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Factsheet-for-Patients-2019-nCoV.pdf)

Factsheet-for-Patients-2019-nCoV.pdf)

UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT
CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX
78754 LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D.
CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
	Nasopharyngeal structure / Unknown		05/13/2020 1:00 PM EDT	05/13/2020 3:37 PM EDT

Authorizing Provider	Result Type
Farook Rahmah MD	MICROBIOLOGY - GENERAL ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
SUNQUEST			
HERRICK MEDICAL CENTER	500 EAST POTTAWATAMIE	TECUMSEH, MI 49286	

- SARS COV 2 (COVID-19) (05/13/2020 1:00 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Specimen	Naso Pharynx			05/13 /2020 3: 38 PM EDT	SUNQUE ST	
Sent to	CLINICAL PATHOLOGY LABORATORIES			05/13 /2020 3: 38 PM EDT	SUNQUE ST	
COVID-19	CPL Report to Follow			05/13 /2020 3: 38 PM EDT	SUNQUE ST	

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
Swab	Nasopharyngeal structure / Unknown		05/13/2020 1:00 PM EDT	05/13/2020 3:37 PM EDT

Authorizing Provider	Result Type
Farook Rahmah MD	MICROBIOLOGY - GENERAL ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
SUNQUEST			

documented in this encounter

Visit Diagnoses

Diagnosis

Cough - Primary
Sore throat
Acute pharyngitis

documented in this encounter

Admitting Diagnoses

Not on filedocumented in this encounter

Administered Medications

Not on filedocumented in this encounter

Additional Health Concerns

Infection	Onset Date	Last Indicated	Resolved Time
COVID-19 Rule-Out	05/13/2020	05/13/2020	05/14/2020 4:42 PM EDT

documented as of this encounter

Care Teams

Team Member	Relationship	Specialty	Start Date	End Date
Rahmah, Farook, MD 1816 Grindley Park Suite 2 Dearborn, MI 48124 333-792-1290 (Work) 373-792-1901 (Fax)	PCP - General	Family Medicine	5/13/20	

documented as of this encounter

Allergies

Not on File from 11/23/2017 to 11/23/2022

Medications

Not on file from 11/23/2017 to 11/23/2022

Active Problems

Not on file

from 11/23/2017 to 11/23/2022

Immunizations

Not on file from 11/23/2017 to 11/23/2022

Social History

Smoking Status as of 11/23/2022

Tobacco Use	Types	Packs/Day	Years Used	Date
Smoking Tobacco: Never Assessed				

Sex Assigned at Birth	Date Recorded
Not on file	

from 11/23/2017 to 11/23/2022

Last Filed Vital Signs

Not on file from 11/23/2017 to 11/23/2022

Plan of Treatment

Not on file

from 11/23/2017 to 11/23/2022

Medical Devices

Not on file from 11/23/2017 to 11/23/2022

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
SARS COV 2 BY NAAT /MOLECULAR (CPL)	Routine	05/13/2020 1:00 PM EDT		Results for this procedure are in the results section.
SARS COV 2 (COVID-19)	Routine	05/13/2020 1:00 PM EDT	Cough Sore throat	Results for this procedure are in the results section.

from 11/23/2017 to 11/23/2022

Results

- SARS CoV 2 INTERP (CPL) (05/13/2020 1:00 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
COVID-19	NEGATIVE	SEE NOTE		05/14 /2020 4: 42 PM EDT	HERRICK MEDICAL CENTER	

Comment:

NOTE

SARS-CoV-2 RNA NOT DETECTED

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 have not been determined. Collection of multiple specimens or types of specimens may be necessary to detect virus. Improper specimen collection and handling, sequence variability under primers/probes, or organism present below the limit of detection may lead to false negative results. Positive and negative predictive values of testing are highly dependent on prevalence. False negative test results are more likely when prevalence is high.

Source	NASOPHARYNGEAL			05/14 /2020 4: 42 PM EDT	HERRICK MEDICAL CENTER	
--------	----------------	--	--	-----------------------------------	------------------------------	--

Comment:

NOTE

The expected result is Negative (Not Detected).

The SARS-CoV-2 test is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria. For lower respiratory tract specimens, the assay is submitted for authorization by FDA under an Emergency Use Authorization (EUA). Testing methodology is real-time RT-PCR. If received as separate collection devices, nasopharyngeal and oro-pharyngeal specimens are combined for analysis. Additional specimens may be split to a separate accession for analysis and reporting as this test includes a single unit of service.

Test results must be correlated with clinical presentation and evaluated in the context of other laboratory and epidemiologic data. Test performance can be affected because the epidemiology and clinical spectrum of infection caused by SARS-CoV-2 is not fully known. For example, the optimum types of specimens to collect and when during the course of infection these specimens are most likely to contain detectable viral RNA may not be known.

This test has not been Food and Drug Administration (FDA) cleared or approved and has been authorized by FDA under an Emergency Use Authorization (EUA). The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of SARS-CoV-2 under Section 564(b)(1) of the Act, 21 U.S.C. section 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Clinical Pathology Laboratories are certified under the

Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. section 263a, to perform high complexity tests.

Fact Sheet for Healthcare Providers:

<https://tinyurl.com/r7awxyh>

(or: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/Factsheet-for-Healthcare-Providers-2019-nCoV.pdf>)

Fact Sheet for Patients:

<https://tinyurl.com/rlqe72t>

(or: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/Factsheet-for-Patients-2019-nCoV.pdf>)

UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT
CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX
78754 LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D.
CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
	Nasopharyngeal structure / Unknown		05/13/2020 1:00 PM EDT	05/13/2020 3:37 PM EDT

Authorizing Provider	Result Type
Farook Rahmah MD	MICROBIOLOGY - GENERAL ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
SUNQUEST			
HERRICK MEDICAL CENTER	500 EAST POTTAWATAMIE	TECUMSEH, MI 49286	

- SARS COV 2 (COVID-19) (05/13/2020 1:00 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Specimen	Naso Pharynx			05/13 /2020 3: 38 PM EDT	SUNQUE ST	
Sent to	CLINICAL PATHOLOGY LABORATORIES			05/13 /2020 3: 38 PM EDT	SUNQUE ST	
COVID-19	CPL Report to Follow			05/13 /2020 3: 38 PM EDT	SUNQUE ST	

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
Swab	Nasopharyngeal structure / Unknown		05/13/2020 1:00 PM EDT	05/13/2020 3:37 PM EDT

Authorizing Provider	Result Type
Farook Rahmah MD	MICROBIOLOGY - GENERAL ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
SUNQUEST			

from 11/23/2017 to 11/23/2022

Visit Diagnoses

Diagnosis	Start Date
Cough	5/13/2020
Sore throat Acute pharyngitis	5/13/2020

from 11/23/2017 to 11/23/2022

Goals

Not on file from 11/23/2017 to 11/23/2022

Additional Health Concerns

Infection	Onset Date	Last Indicated	Resolved Time
COVID-19 Rule-Out	05/13/2020	05/13/2020	05/14/2020 4:42 PM EDT

from 11/23/2017 to 11/23/2022

Care Teams

Team Member	Relationship	Specialty	Start Date	End Date
Rahmah, Farook, MD 1816 Grindley Park Suite 2 Dearborn, MI 48124 333-792-1900 (Work) 393-792-1801 (Fax)	PCP - General	Family Medicine	5/13/20	

from 11/23/2017 to 11/23/20

Encounter Details

Date	Type	Department	Care Team	Description
07/03 /2019	Hospital Encounter	OHMC Laboratory 18101 Oakwood Dearborn, MI 48124 313-593-7994	Turfah, Fuad H, MD 1811 Monroe Dearborn, MI 48124 313-565-4010 (Work) 313-565-7208 (Fax)	Encounter for screening for malignant neoplasm of colon

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Smoking Tobacco: Former	Cigarettes	2	2	Quit: 12/28/1980
Smokeless Tobacco: Never				
Alcohol Use	Standard Drinks/Week	Comments		
Yes	4 (1 standard drink = 0.6 oz pure alcohol)	occasional		
Sex Assigned at Birth	Date Recorded			
Not on file				

documented as of this encounter

Medications at Time of Discharge

Medication	Sig	Dispensed	Refills	Start Date	End Date
aspirin (ECOTRIN) 81 MG PO Tablet Delayed Response	take 81 mg by mouth once daily.		0		
Cholecalciferol (VITAMIN D3) 2000 UNITS PO Chew Tab	take by mouth.		0		
docusate (COLACE) 100 MG PO Cap	take 1 Cap by mouth once daily.	50 Cap	0	12/29/2016	
hydrocodone-acetaminophen (NORCO) 7.5-325 MG PO Tab	take 1 Tab by mouth every 4 hours as needed for FOR SEVERE PAIN.	30 Tab	0	12/29/2016	
ondansetron (ZOFTRAN) 4 MG PO Tab	take 1 Tab by mouth every 8 hours as needed for FOR NAUSEA/VOMITING.	20 Tab	0	12/29/2016	
lansoprazole (PREVACID) 15 MG PO TABLET DISPERSIBLE	take 15 mg by mouth.		0		07/30/2020

documented as of this encounter

Plan of Treatment

Not on file

documented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
OHS SURGICAL HISTOLOGY	Routine	07/03/2019 10: 51 AM EDT		Results for this procedure are in the results section.

documented in this encounter

Results

- Surgical (07/03/2019 10:51 AM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Surgical Histology	<p>Final Pathologic Diagnosis: Biopsy terminal ileum: Terminal ileal mucosa with no pathologic changes.</p> <p>Signed out</p>				OHS LAB	

By: Anjana
S. Soman,
M.D.
/Electronical
ly Signed
Out 7/5
/2019 12:35
Patient:
BOURKE,
THOMAS M
Specimen #:
OVS19-2272
Accessione
d: 7/3/2019
10:51
Diagnosis /
History:
Screening
Diverticulosi
s, rule out
ileitis

Procedure:
Colonoscop
y with
biopsy

Specimen
(s)
Received:
Bx terminal
ileum

Microscopic
Description:
Section
shows
portion of
unremarkab
le terminal
ileal
mucosa.
There is no
evidence of
inflammatio
n,
dysplasia
or
malignancy.

Gross
Description:
Labeled
biopsy
terminal
ileum and
is two tan
bits
measuring
0.2 and 0.4
cm. All in
one
cassette.

Nicholas
Chalifoux

	Code(s): A: 88305				
Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time	
			07/03/2019 10:51 AM EDT	07/03/2019 10:51 AM EDT	
Authorizing Provider	Result Type				
Fuad P Turfa MD	OHS PATHOLOGY/CYTOLOGY ORDERABLES				
Performing Organization	Address	City/State/ZIP Code	Phone Number		
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073			
OHS LAB					

documented in this encounter

Visit Diagnoses

Not on file documented in this encounter

Care Teams

Team Member	Relationship	Specialty	Start Date	End Date
PCP - General Rahman, Sumi, MD 1816 Grindley Park Suite 3 Dearborn, MI 48124 313-792-1292 (Work) 313-792-1281 (Fax)		Family Medicine	12/29/16	

documented as of this encount

Encounter Details

Date	Type	Department	Care Team	
06/11 /2019	Hospital Encounter	OHMC Laboratory 18101 Westwood Dearborn, MI 48124 313-533-7894	Rahman, Farook, MD 1816 Grindley Park Suite 2 Dearborn, MI 48124 313-722-1200 (Work) 313-732-1201 (Fax)	Description Encounter for general adult medical examination without abnormal findings

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Smoking Tobacco: Former	Cigarettes	2	Quit: 12/28/1980	
Smokeless Tobacco: Never				
Alcohol Use	Standard Drinks/Week	Comments		
Yes	4 (1 standard drink = 0.6 oz pure alcohol)	occasional		
Sex Assigned at Birth	Date Recorded			
Not on file				

documented as of this encounter

Medications at Time of Discharge

Medication	Sig	Dispensed	Refills	Start Date	End Date
aspirin (ECOTRIN) 81 MG PO Tablet Delayed Response	take 81 mg by mouth once daily.		0		
Cholecalciferol (VITAMIN D3) 2000 UNITS PO Chew Tab	take by mouth.		0		
docusate (COLACE) 100 MG PO Cap	take 1 Cap by mouth once daily.	50 Cap	0	12/29/2016	
hydrocodone-acetaminophen (NORCO) 7.5-325 MG PO Tab	take 1 Tab by mouth every 4 hours as needed for FOR SEVERE PAIN.	30 Tab	0	12/29/2016	
ondansetron (ZOFTRAN) 4 MG PO Tab	take 1 Tab by mouth every 8 hours as needed for FOR NAUSEA/VOMITING.	20 Tab	0	12/29/2016	
lansoprazole (PREVACID) 15 MG PO TABLET DISPERSIBLE	take 15 mg by mouth.		0		07/30/2020

documented as of this encounter

Plan of Treatment

Not on file

documented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
OHS TSH (THYROID STIMULATING HORMONE)	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.
OHS PROSTATE SPECIFIC AG DIAGNOSTIC, TOTAL	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.
OHS LIPID PNL-CHOL,TRIG, HDL,VLDL,LDL,NON-HDL	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.
OHS COMPREHENSIVE METABOLIC PANEL	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.
OHS CBC W/ AUTO DIFF (MAN. DIFF IF NEED)	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.
OHS B12 (VITAMIN B12)	Routine	06/11/2019 6:58 PM EDT		Results for this procedure are in the results section.

documented in this encounter

Results

- TSH (Thyroid Stimulating Hormone) (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
TSH	0.69	0.40 - 4.50 uIU /mL			OHS LAB	

Comment: Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn,MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

- Prostate Specific Ag Diagnostic, Total (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
PSA, Diagnostic	0.8	0.0 - 4.0 ng /mL			OHS LAB	

Comment:

The above normal values are based on the traditional and FDA approved decision limits. Others, including the NCCN are recommending lowering the upper limit of normal to less than 2.5 ng/mL as using a 4 ng/ml upper limit misses 20% of cancers. Also, significant changes in total PSA values (0.35 ng/mL) per year should be considered suspicious even in the "normal" range. Additionally, % Free PSA can be used as a factor to guide biopsy decisions. See Prostate Cancer Early Detection Guidelines at www.nccn.org for details.
Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn,MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

- (ABNORMAL) Lipid Pnl-Chol,Trig,HDL,VLDL,LDL,Non-HDL (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Cholesterol	211 (H)	100 - 199 mg/dL			OHS LAB	
Triglycerides	70	<150 mg/dL			OHS LAB	
HDL Cholesterol	66	40 - 90 mg /dL			OHS LAB	
VLDL Cholesterol	14	mg/dL			OHS LAB	
LDL Cholesterol	131 (H)	<100 mg/dL			OHS LAB	
Non-HDL Cholesterol	145	mg/dL			OHS LAB	
Chol/HDL Ratio	3.0	<6.0			OHS LAB	
Interpretation, Lipid Profile	SEE NOTES				OHS LAB	

Comment:

Interpretation

Cholesterol:
Desirable: <200 mg/dL
Borderline High: 200-239 mg/dL
High: >=240 mg/dL
Triglycerides:
Normal: <150 mg/dL
Borderline High: 150-199 mg/dL
High: 200-499 mg/dL
Very High: >=500 mg/dL
HDL Cholesterol:
Low: <40 mg/dL
Normal: 40-59 mg/dL
High: >=60 mg/dL
LDL Cholesterol:
Optimal: <100 mg/dL
Above Optimal: 100-129 mg/dL
Borderline High: 130-159 mg/dL
High: 160-189 mg/dL
Very High: >=190 mg/dL
Non-HDL Cholesterol:
Optimal: <130 mg/dL
Above Optimal: 130-159 mg/dL
Borderline High: 160-189 mg/dL
High: 190-219 mg/dL
Very High: >220 mg/dL
Reference: Third report NCEP Panel 2004
Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn,MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

- (ABNORMAL) CBC w/ Auto Diff (Man. Diff if need) (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
White Blood Cells	5.7	4.0 - 11.3 Thous /uL			OHS LAB	
Red Blood Cells	5.31	4.30 - 5.90 Million /uL			OHS LAB	
Hemoglobin	15.6	13.6 - 17.6 g /dL			OHS LAB	
Hematocrit	48.9	40.0 - 50.0 %			OHS LAB	
Mean Corpuscular Vol	92.0	82.0 - 97.0 fL			OHS LAB	
Mean Corpuscular Hgb	29.4	27.3 - 33.4 pg			OHS LAB	
Mean Corp Hgb Conc	31.9 (L)	32.0 - 36.0 g /dL			OHS LAB	
Red Blood Cell Distribution Width	14.9 (H)	11.6 - 14.8 %			OHS LAB	
Platelet Count	288	150 - 450 Thous /uL			OHS LAB	
Mean Platelet Volume	10.4	7.4 - 10.4 fL			OHS LAB	
Differential Method	Automated Diff. See Abs values for normals.				OHS LAB	
% Neutrophils	71.3	%			OHS LAB	
% Lymphocytes	20.3	%			OHS LAB	
% Monocytes	5.4	%			OHS LAB	
% Eosinophils	1.9	%			OHS LAB	

% Basophils	1.1	%			OHS LAB	
Absolute Neutrophils	4.1	1.8 - 8.0 Thous /uL			OHS LAB	
Absolute Lymphocytes	1.2	0.6 - 4.5 Thou /uL			OHS LAB	
Absolute Monocytes	0.3	0.2 - 1.4 Thou /uL			OHS LAB	
Absolute Eosinophils	0.1	0.0 - 0.8 Thou /uL			OHS LAB	
Absolute Basophils	0.1	0.0 - 0.2 Thou /uL			OHS LAB	

Comment: Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn, MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

- Comprehensive Metabolic Panel (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
-----------	-------	--------------	-------------	------------------	-----------------	-----------------------

Sodium	138	135 - 145 MMOL /L			OHS LAB	
Potassium	4.5	3.5 - 5.2 mmol /L			OHS LAB	
Chloride	103	98 - 111 mmol /L			OHS LAB	
Total CO2	24	20 - 29 mmol /L			OHS LAB	
Anion Gap	11	5-20 mmol /L			OHS LAB	
Glucose	107	60 - 139 mg/dL			OHS LAB	
Blood Urea Nitrogen	13	7-25 mg/dL			OHS LAB	
Creatinine	1.10	0.60 - 1.30 mg/dL			OHS LAB	
Glomerular Filtration Rate, Non-Black	73	>60 mL /min/1.73 m2			OHS LAB	
Glomerular Filtration Rate, Black	85	>60 mL /min/1.73 m2			OHS LAB	
Calcium	9.7	8.5 - 10.5 mg/dL			OHS LAB	
Protein, Total	7.1	6.4 - 8.3 g /dL			OHS LAB	
Albumin	4.6	3.5 - 5.1 gm /dL			OHS LAB	
Bilirubin, Total	0.4	0.3 - 1.2 mg /dL			OHS LAB	
AST (SGOT)	25	<35 U /L			OHS LAB	
ALT (SGPT)	24	9-47 U/L			OHS LAB	
Alkaline Phosphatase	52	33 - 120 U /L			OHS LAB	

Comment: Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn, MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

- B12 (Vitamin B12) (06/11/2019 6:58 PM EDT):

Component	Value	Ref Range	Test Method	Analysis Time	Performed At	Pathologist Signature
Vitamin B12	851	271 - 1,000 pg/mL			OHS LAB	

Comment:

Interpretive Data:
Normal: >180 pg/mL
Borderline: 145-180 pg/mL
Deficient: <145 pg/mL
Expected ranges established in patients
with megaloblastic anemia.
Beaumont Laboratory, 18101 Oakwood Blvd, Dearborn, MI 48124

Specimen (Source)	Anatomical Location / Laterality	Collection Method / Volume	Collection Time	Received Time
			06/11/2019 6:58 PM EDT	06/12/2019 6:58 PM EDT

Authorizing Provider	Result Type
Doctor Outreach	OHS LAB BLOOD ORDERABLES

Performing Organization	Address	City/State/ZIP Code	Phone Number
OHS LAB	3601 W. 13 Mile Rd	Royal Oak, MI 48073	
OHS LAB			

documented in this encounter

Visit Diagnoses

Not on file documented in this encounter

